MetaboliccareToday.com

Metabolic Care Today shares news, insights, and updates to keep healthcare professionals informed on research and care in metabolic disorders.

[Diabetes Care, an ADA research journal 🌟 @DiabetesCareADA]

Across 4 prospective cohorts (n=3,263) including people with/without type 2 diabetes at profiling, IgG glycosylation peaks were linked to diabetic nephropathy but were less informative for neuropathy.

Read ➡️ https://t.co/HHWZpXjo1o

@AmDiabetesAssn @ADA_DiabetesPro @ADA_Pubs

[Neil Floch MD @NeilFlochMD]

GLP-1ra and gut hormones improve medical conditions independent of weight loss.

[MetaboliccareToday.com @MetabolicCare]

Setmelanotide significantly reduced BMI and hunger in patients with acquired hypothalamic obesity in a phase 3 trial published in @NEJM.

At 52 weeks:
✅ BMI: −16.5% vs +3.3% with placebo
✅ Greater reductions in hunger scores

Read more: https://t.co/9S9wShWwbi @MWeintraubMD

[MetaboliccareToday.com @MetabolicCare]

How could obesity treatment evolve beyond the scale?
@carel_leroux breaks down SYNCHRONIZE-1 and SYNCHRONIZE-MASLD data, including survodutide's effects on liver fat, metabolic health, and future cardiovascular outcomes.
🎥 https://t.co/SMDq225qlI @ucddublin @MWeintraubMD

[MetaboliccareToday.com @MetabolicCare]

Dr. Tim Garvey discusses the ADA 2026 CagriSema data, the promise of amylin-GLP-1 combinations, and why amylin-based therapies could become a major new option in obesity and type 2 diabetes care.
Watch now: https://t.co/EBg0cBHVbo @ADA_DiabetesPro @MWeintraubMD @TheAACE

[Michael Albert, MD @MichaelAlbertMD]

A Yale researcher went shopping for a drug I commonly prescribe.
49 websites.
45 sold it to her.
Two did it in under five minutes.
Only 55% asked whether she had an eating disorder.

The drug isn't the problem. The absence of a real doctor in the room is. 🧵

[Scott Isaacs @scottisaacsmd]

New narrative review shows GLP1 based agents produce ~30% fat free mass loss as a percentage of total weight loss. There are major gaps in how we quantify body composition, muscle loss, and #sarcopenia risk and need imaging beyond DXA plus functional outcomes to judge “weight loss quality” in this class.
https://t.co/clbNsX0obM

[Carolyn Lam @lamcardio]

Had the privilege of sitting down with @CellPressNews for a Q&A in Med.

Spoke about things close to my heart: why access, not knowledge, is the real bottleneck in cardiology, and why that led me to co-found @us2_ai

🔗Full Q&A in Med : https://t.co/znaX7iwy9z

[Michael Albert, MD @MichaelAlbertMD]

A lot of people have asked how they can keep up with obesity clinical trials, and many are interested in participating.

So I built a free, live tracker of active obesity drug trials.

You can explore ongoing studies, see what's recruiting, and learn more here: https://t.co/7dj5bwrwNn

[Michael Weintraub, MD @MWeintraubMD]

💉 Setmelanotide is recently approved in acquired hypothalamic obesity. Published yesterday are the full phase 3 TRANSCEND trial results in NEJM

🧠 Acquired hypothalamic obesity is caused by brain tumors, surgery, or radiation. Severe hyperphagia and weight gain occurs through a disrupted MC4R pathway. Until now, there has been no approved pharmacotherapy that targets the underlying mechanism.

🔬 Setmelanotide, a MC4R agonist, directly targets the hypothalamic dysfunction, an area GLP-1s can't fully target with mixed results.

📊 In TRANSCEND, 120 children and adults setmelanotide vs. placebo for 52 weeks.

⬇️ Setmelanotide: 16.5% reduction in BMI
⬆️ Placebo: 3.3% increase in BMI
📐 Treatment difference: -19.8 percentage points (P<0.001)

Published yesterday in the New England Journal of Medicine: https://t.co/SHHqFHg77I

[MetaboliccareToday.com @MetabolicCare]

At #ADA2026, obesity medicine took another step beyond GLP-1s.
@MWeintraubMD discusses key data on retatrutide, survodutide, oral GLP-1 therapies, and emerging amylin-based agents—and what they could mean for the future of obesity care.
Watch: https://t.co/QoZTZbxHvu @nyulangone

[Melanie Jay @drmelaniejay]

@MetabolicCare @MWeintraubMD Thank you for hosting this important discussion. We need to promote scientific dialogue and free speech

[MetaboliccareToday.com @MetabolicCare]

What happens when conference enforcement becomes the story instead of the science?
@drmelaniejay discusses the recent ADA Scientific Sessions controversy, scientific dialogue, policy engagement, and lessons for future meetings.
Watch: https://t.co/c6YxYWS440 @MWeintraubMD

[Carolyn Lam @lamcardio]

🚨 New publication: AHA/ACC/ESC/WHF Expert Consensus on the Second Universal Definition of Heart Failure (2026) is out.

Honoured to be part of the writing group on this global effort. It moves us toward more nuanced, individualised HF care!

🔗https://t.co/0w2W4QQDbc

[Diabetes Care, an ADA research journal 🌟 @DiabetesCareADA]

Renal lipotoxicity drives diabetic kidney disease and CKM syndrome. Excess lipid uptake, poor oxidation, and mitochondrial dysfunction fuel renal inflammation and fibrosis, revealing new targets.

Read here ➡️ https://t.co/23SjwU6QUD

@AmDiabetesAssn @ADA_DiabetesPro @ADA_Pubs

[Scott Isaacs @scottisaacsmd]

New review on epidemiology of cardiometabolic multiple long-term conditions #MLTC. Diseases including T2D, CVD, CKD and MASLD/MASH are considered a major global health challenge, driven by shared risks like obesity, insulin resistance and social disadvantage.
https://t.co/CjxoSMQ8Do

[MetaboliccareToday.com @MetabolicCare]

Tirzepatide may go beyond glucose control, new data show:
• Potential kidney benefits
• Strong option for high-risk T2D + ASCVD
• Greater weight loss vs GLP-1s
• GI tolerability still key
https://t.co/jZKgzCAcTK @MonashUni @MonashHeart @TheLancetEndo @MWeintraubMD @PZoungas

[Michael Weintraub, MD @MWeintraubMD]

💉 Survodutide, a dual GLP-1/glucagon agonist, with Phase 3 results specifically in those with metabolic-associated steatotic liver disease (MASLD).

⬇️ 84% of survodutide group met primary endpoint of >30% liver fat content reduction by MRI, compared to 24% of placebo.

⬇️ Survodutide group had 12% weight reduction vs. 1% with placebo.

🔑 Glucagon agonism likely has direct liver benefits, independent of weight loss

📊 SYNCHRONIZE-MASLD published in Nature Medicine: https://t.co/ZOJ1HILgAH

[MetaboliccareToday.com @MetabolicCare]

Survodutide shows strong phase 3 results at #ADA2026:
🔹 16.6% weight loss (vs 3.2% placebo)
🔹 Up to 63% ↓ liver fat
🔹 84% achieved ≥30% liver fat reduction in MASLD
A dual GLP-1/glucagon approach targeting metabolic dysfunction. @carel_leroux @McMasterU @MWeintraubMD

[Diabetes Care, an ADA research journal 🌟 @DiabetesCareADA]

Automated insulin delivery resulted in superior intrapartum and early postpartum glycemia compared to standard insulin delivery, with no safety concerns.

Read here ➡️ https://t.co/HLeMdBo8bq

@AmDiabetesAssn @ADA_DiabetesPro @ADA_Pubs